Versant Capital Management’s Boston Scientific BSX Stock Holding History

Versant Capital Management’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$214K	Sell	5,005 -372	-7%	-$20.2K	0.02%	595
2026 Q1	$337K	Buy	5,377 +50	+0.9%	+$4K	0.03%	388
2025 Q4	$508K	Sell	5,327 -1,168	-18%	-$115K	0.06%	218
2025 Q3	$634K	Buy	6,495 +2,797	+76%	+$290K	0.09%	156
2025 Q2	$397K	Sell	3,698 -1,737	-32%	-$176K	0.06%	237
2025 Q1	$548K	Buy	5,435 +3,121	+135%	+$314K	0.09%	137
2024 Q4	$207K	Buy	2,314 +1,208	+109%	+$106K	0.04%	170
2024 Q3	$92.7K	Buy	1,106 +240	+28%	+$18.9K	0.02%	255
2024 Q2	$66.7K	Buy	866 +718	+485%	+$52.6K	0.02%	301
2024 Q1	$10.1K	Hold	148	–	–	﹤0.01%	773
2023 Q4	$8.56K	Sell	148 -8	-5%	-$427	﹤0.01%	797
2023 Q3	$8.24K	Hold	156	–	–	﹤0.01%	796
2023 Q2	$8.44K	Buy	156 +76	+95%	+$3.97K	﹤0.01%	841
2023 Q1	$4K	Hold	80	–	–	﹤0.01%	1028
2022 Q4	$3.7K	Hold	80	–	–	﹤0.01%	979
2022 Q3	$3K	Buy	80 +50	+167%	+$2.01K	﹤0.01%	952
2022 Q2	$1K	Hold	30	–	–	﹤0.01%	1213
2022 Q1	$1K	Sell	30 -47	-61%	-$2.04K	﹤0.01%	1238
2021 Q4	$3K	Hold	77	–	–	﹤0.01%	1015
2021 Q3	$3K	Hold	77	–	–	﹤0.01%	1014
2021 Q2	$3K	Sell	77 -162	-68%	-$6.82K	﹤0.01%	1022
2021 Q1	$9K	Sell	239 -120	-33%	-$4.54K	﹤0.01%	810
2020 Q4	$12K	Buy	359 +21	+6%	+$757	﹤0.01%	669
2020 Q3	$12K	Hold	338	–	–	0.01%	592
2020 Q2	$11K	Buy	338 +7	+2%	+$252	0.01%	593
2020 Q1	$10K	Buy	331 +166	+101%	+$6.49K	0.01%	541
2019 Q4	$7K	Hold	165	–	–	﹤0.01%	811
2019 Q3	$6K	Buy	165 +17	+11%	+$720	﹤0.01%	880
2019 Q2	$6K	Hold	148	–	–	﹤0.01%	893
2019 Q1	$5K	Sell	148 -5	-3%	-$191	﹤0.01%	1092
2018 Q4	$5K	Hold	153	–	–	﹤0.01%	1010
2018 Q3	$5K	Buy	153 +5	+3%	+$175	﹤0.01%	1078
2018 Q2	$4K	Hold	148	–	–	﹤0.01%	1125
2018 Q1	$4K	Hold	148	–	–	﹤0.01%	1110
2017 Q4	$3K	Sell	148 -6	-4%	-$165	﹤0.01%	1229
2017 Q3	$4K	Buy	154 +6	+4%	+$166	﹤0.01%	1090
2017 Q2	$4K	Hold	148	–	–	﹤0.01%	1086
2017 Q1	$3K	Hold	148	–	–	﹤0.01%	1140
2016 Q4	$3K	Sell	148 -52	-26%	-$1.14K	﹤0.01%	1108
2016 Q3	$4K	Buy	200 +67	+50%	+$1.6K	﹤0.01%	1025
2016 Q2	$3K	Hold	133	–	–	﹤0.01%	1060
2016 Q1	$2K	Sell	133 -11	-8%	-$193	﹤0.01%	1113
2015 Q4	$2K	Buy	+144	New	+$2.58K	﹤0.01%	1114

Other funds holding BSX

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

FFM

Fisher Funds Management Auckland, New Zealand $3.52B AUM 17.59% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

ZIC

ZWJ Investment Counsel Atlanta, Georgia $3.09B AUM 39.43% 1-Year Est. Return

ASR Vermogensbeheer Utrecht, Netherlands $9.71B AUM 37.32% 1-Year Est. Return

GIA

Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return

Gradient Investments Arden Hills, Minnesota $7.25B AUM 20.71% 1-Year Est. Return

Versant Capital Management's BSX Position: Q2 2026 in Review

Versant Capital Management reduced its Boston Scientific (BSX) stake by 6.9% in Q2 2026, selling an estimated $20.2K and leaving 5,005 shares worth $214K. The position accounts for 0.02% of the portfolio, ranked #595.

Versant Capital Management first reported a position in BSX in Q4 2015 and has held it in 43 quarters since. The position peaked at $634K in Q3 2025. 209 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

Versant Capital Management held 5,005 shares of Boston Scientific worth $214K as of Q2 2026.
Versant Capital Management sold 372 Boston Scientific shares in Q2 2026, an estimated $20.2K.
Boston Scientific made up 0.02% of Versant Capital Management's portfolio in Q2 2026, its #595 holding.
Versant Capital Management first reported a position in Boston Scientific in Q4 2015 and has held it in 43 quarters since.
Versant Capital Management's Boston Scientific position peaked at $634K in Q3 2025.
209 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.